Yahoo Web Search

  1. Merck & Co., Inc. (NYSE:MRK) Is An Attractive Dividend Stock, Here's Why

    Simply Wall St. via Yahoo FinanceApr 10 12:52 PM

    The stock currently pays out a dividend yield of 2.7%, and has a market cap of US$209b. In the near future, analysts are predicting lower payout ratio of 39% which, assuming the share price stays the same, leads to a dividend yield of 2.9%.

  2. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK.

  3. AstraZeneca's Selumetinib Gets Breakthrough Therapy Status

    Zacks via Yahoo FinanceApr 01 19:36 PM

    AstraZeneca is developing selumetinib in partnership with Merck & Co. Inc. MRK. AstraZeneca and Merck entered into a co-development and co-commercialization ...

  4. Merck (MRK) closed the most recent trading day at $80.95, moving -0.25% from the previous trading session. This move lagged the S&P 500's daily gain of 0.11%. Heading into today, shares ...

  5. Merck & Co., Inc. MRK announced that its PD-L1 therapy, Keytruda, has gained conditional approval for use in combination with chemotherapies for first-line metastatic nonsquamous ...

  6. Merck & Co., Inc. MRK announced that the FDA granted approval to its blockbuster anti-PD-1 therapy, Keytruda for an expanded first-line lung cancer indication. It is now ...

  7. NASDAQ: ANGO)' Cyclerion Therapeutics Inc (NASDAQ: CYCNV)(spun off from Ironwood Pharmaceuticals, Inc. NASDAQ: IRWD) GENFIT S.A. (NASDAQ: GNFT) Masimo Corporation (NASDAQ: MASI ...

  8. Merck (MRK) Stock Moves -0.11%: What You Should Know

    Zacks via Yahoo FinanceApr 02 21:50 PM

    This change lagged the S&P 500's daily of 0%. Heading into today, shares of the pharmaceutical company had gained 2.37% over the past month, outpacing the Medical sector's loss of 0.21% and ...

  9. Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval

    Zacks via Yahoo FinanceApr 10 14:16 PM

    Amgen, Inc. AMGN and its partner UCB announced that the FDA has approved Evenity (romosozumab-aqqg) for treating osteoporosis in postmenopausal women at high risk of fracture. Evenity ...

  10. Advaxis, Inc. ADXS announced encouraging updated data from its ongoing phase I/II study — KEYNOTE-046 — evaluating its pipeline candidate, ADXS-PSA, in combination with Merck's ...